axin

JW 67 is an inhibitor of canonical Wnt pathway signaling. JW 67 rapidly reduced active β-catenin with a subsequent downregulation of Wnt target genes, including AXIN2, SP5, and NKD1.

Semaxinib (SU5416) is a potent and selective VEGFR2 inhibitor (IC50: 1.23 μM), exhibiting a 20-fold greater selectivity for VEGFR2 over PDGFRβ, with no activity against InsR, EGFR, and FGFR. Semaxinib reversibly inhibits ATP binding to the tyrosine kinase domain of VEGFR2, potentially inhibiting VEGF-stimulated endothelial cell migration and proliferation, thereby reducing tumor microvasculature.

Autotaxin-IN-3 is an inhibitor of Autotaxin (IC50 = 2.4 nM) which is responsible for the increase in lysophosphatidic acid in ascites and plasma.

Autotaxin-IN-4 is an Autotaxin inhibitor. It has the potential to treat idiopathic pulmonary fibrosis.

Venlafaxine hydrochloride (Wy 45030 hydrochloride) is a cyclohexanol and phenylethylamine derivative functioning as a serotonin and noradrenaline reuptake inhibitor (SNRI) used as an antidepressive agent.

Desvenlafaxine (O-Desmethylvenlafaxine) is a cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a serotonin and noradrenaline reuptake inhibitor (SNRI) and is used as an antidepressive agent.

Venlafaxine (Wy 45030), an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Desvenlafaxine succinate hydrate (WY 45233 Succinate) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).

Autotaxin-IN-5 is an Autotaxin inhibitor. It has the potential to treat idiopathic pulmonary fibrosis.

Autotaxin modulator 1 (compound 12b) is an autotaxin (ATX) enzyme inhibitor applicable for studying demyelination and tumours.

Autotaxin-IN-1 is a potent autotaxin inhibitor used in the treatment of osteoarthritis pain. It exhibits favorable potency (IC50=2.2 nM), pharmacokinetic (PK) properties, and a robust PK/pharmacodynamic (PD) relationship[1].

Autotaxin-IN-7 (45) is a pyridine-2-carboxylic acid derivative exhibiting sub-nanomolar inhibition of ATX (IC50 = 0.086 nM) and features excellent cardiac safety (hERG > 30 μM) with minimal toxicity to fibroblasts. It inhibits the TGF-β/Smad signaling pathway, reducing α-smooth muscle actin (α-SMA) and extracellular matrix components (ECM). Autotaxin-IN-7 (45) can be used in pulmonary fibrosis research.

(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative with potential antineoplastic activity.

Manifaxine, a norepinephrine-dopamine reuptake inhibitor, is used potentially for the treatment of attention deficit.

Spirolaxine, a natural product isolated from Sporotrichum laxum ATCC 15155, has shown a variety of biological activities including promising anti-Helicobacter pylori property.

Axinylsterol is a biochemical.

Cephalotaxine (ZINC19795976) is an antiviral and an antitumor agent.

Fraxin (Fraxoside) is a glucoside of fraxetin.

(S)-O-Desmethyl Venlafaxine N-Oxide, an N-oxide derivative of (S)-O-Desmethyl Venlafaxine, is an active metabolite of the serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant Venlafaxine[1][2].

Fraxinol is a predicted metabolite generated by BioTransformer¹ that is produced by the metabolism of 5, 7-dimethoxy-2h-chromen-2-one. It is generated by cyp1a2, cyp2a6, cyp2b6, cyp2c9, cyp2c19, and cyp2e1 enzymes via an aromatic-hydroxylation-of-fused-be

Ansofaxine, an SNRI compound, is commonly utilized in depression research as a serotonin-norepinephrine reuptake inhibitor.

Ansofaxine hydrochloride (LY03005) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723, 763 and 491 nM, respectively).

(S)-Venlafaxine, the (S)-configuration of Venlafaxine, is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor with antidepressant activity [1].

1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding-deterrent activity, inhibition of growth, and larvicidal activity. 3. Fraxinellone has effect in the midgut metabolism of Mythimna separata (M. separata), via protease (especially the weak alkaline trypsin-like enzyme), carboxylesterase and glutathione S-transferase.